BMS-708163 (Avagacestat) - γ-Secretase Inhibitor. CAS# 1146699-66-2 B-PNP InChi: InChI=1S/C29H44F2N6O2/c1-21(2)36-14-7-22(8-15-36)32-27-23-19-25(38-3)26(39-18-6-13-35-11-4-5-12-35)20-24(23)33-28(34-27)37-16-9-29(30

InChi: InChI=1S/C29H44F2N6O2/c1-21(2)36-14-7-22(8-15-36)32-27-23-19-25(38-3)26(39-18-6-13-35-11-4-5-12-35)20-24(23)33-28(34-27)37-16-9-29(30

A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity

InChi: InChI=1S/C16H18N4O2/c21-15(20-7-1-2-8-20)11-18-16(22)19-14-4-3-13-10-17-6-5-12(13)9-14/h3-6

(2016) Nat Commun

Scheuermann TH

BMS-708163 (Avagacestat) - γ-Secretase Inhibitor. CAS# 1146699-66-2 B-PNP InChi: InChI=1S/C29H44F2N6O2/c1-21(2)36-14-7-22(8-15-36)32-27-23-19-25(38-3)26(39-18-6-13-35-11-4-5-12-35)20-24(23)33-28(34-27)37-16-9-29(30BMS 708163 (Avagacestat), CAS No. 1146699 66 2, is a potent, selective and orally bioavailable secretase inhibitor with an IC50 of 0. 3 nM for APP cleavage. It is 190 fold more selective for APP than Notch, having an IC50 of 58 nM for Notch. Phase I clinical trial studies showed that in humans, BMS 708163 decreased CSF A40 and A42 approximately 30% following daily dose of 100 mg after 28 days and by 60% at daily dose of 150 mg. Product information CAS